CMS Proposes Rule Codifying Medicare Drug Price Negotiation Program
On June 16, 2026, CMS published a proposed rule to codify the Medicare Drug Price Negotiation Program established by the Inflation Reduction Act of 2022. The rule would formalize existing program guidance, introduce new policy proposals, and establish the regulatory framework for drug selection, negotiation, re-negotiation, compliance monitoring, and civil monetary penalties. The proposed rule affects Medicare Part D plans and manufacturers. Public comments on the proposed rule are due approximately 60 days after publication in the Federal Register.
Medicare Part D drug pricing changes directly affect Medicaid managed care organizations through Medicaid-Medicare dual eligible populations and potential spillover effects on Medicaid pharmacy benefit management and supplemental rebate negotiations.
Pharmacy · Managed Care · Finance
You might also like